Scientists from UC Davis Center for Surgical Bioengineering, the MIND Institute and UC Berkeley’s Murthy Lab are developing ...
The new method is designed to focus specifically on pain-related signals, without interfering with normal activity in other ...
Two of Opus's seven gene therapy assets are in clinical trials, with additional programs expected to enter the clinic.
GlobalData on MSN
Ocugen sets sights on Phase III after GA gene therapy win
GlobalData is the parent company of Clinical Trials Arena. "Ocugen sets sights on Phase III after GA gene therapy win" was ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
The FDA granted fast track status to VectorY’s VTx-002, an antibody gene therapy targeting TDP-43 protein aggregates in ALS.
The company has made more than 50 deals for its proprietary technology as it looks forward to a potentially “transformative” ...
Osteoarthritis is a highly prevalent joint disease that leads to cartilage breakdown, pain and disability, yet there are ...
"Regulatory flexibility must be tailored for cell and gene therapies," commented FDA Commissioner Marty Makary. "These are ...
Ocugen has announced the publication of positive results from its phase 1 GARDian1 trial of OCU410ST, a gene therapy for ...
Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due to ...
Genethon, a leading laboratory in gene therapy for rare diseases, today announced that it has entered into an exclusive, worldwide licensing agreement with AskBio, a gene therapy company wholly owned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback